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Background: This study evaluated the safety of portal vein embolization (PVE), its impact on future
liver remnant (FLR) volume and regeneration, and subsequent effects on outcome after liver resection.
Methods: Records of 112 patients were reviewed. Standardized FLR (sFLR) and degree of hypertrophy
(DH; difference between the sFLR before and after PVE), complications and outcomes were analysed to
determine cut-offs that predict postoperative hepatic dysfunction.
Results: Ten (8·9 per cent) of 112 patients had PVE-related complications. Postoperative complications
occurred in 34 (44 per cent) of 78 patients who underwent hepatic resection and the 90-day mortality
rate was 3 per cent. A sFLR of 20 per cent or less after PVE or DH of not more than 5 per cent (versus
sFLR greater than 20 per cent and DH above 5 per cent) had a sensitivity of 80 per cent and a specificity
of 94 per cent in predicting hepatic dysfunction. Overall, major and liver-related complications, hepatic
dysfunction or insufficiency, hospital stay and 90-day mortality rate were significantly greater in patients
with a sFLR of 20 per cent or less or DH of not more than 5 per cent compared with patients with higher
values.
Conclusion: DH contributes prognostic information additional to that gained by volumetric evaluation
in patients undergoing PVE.
Paper accepted 4 June 2007
Published online 22 June 2007 in Wiley InterScience (www.bjs.co.uk). DOI: 10.1002/bjs.5836
Introduction
Major and extended hepatectomies are increasingly
performed in patients with hepatobiliary malignancies to
achieve a complete resection and provide a chance of
cure1–4. Extensive resection of liver parenchyma, however,
increases the risk of postoperative hepatic dysfunction
or hepatic insufﬁciency. Although the risk of hepatic
insufﬁciency is inﬂuenced by multiple factors, recent
studies have emphasized an association between volume
and function of the residual liver2,5–9.
Portal vein embolization (PVE) has been used to
reduce the risk of postoperative hepatic insufﬁciency in
patients undergoing hepatic resection10,11. PVE stimulates
hypertrophy of the non-embolized liver, increasing the
volume and function of the future liver remnant (FLR)12–14
and improving the results of postoperative liver function
tests15. Several studies have demonstrated the clinical value
of PVE before liver resection for metastatic tumours8,16,17,
hepatocellular carcinoma18,19 and biliary tract cancer2,10.
Despite growing worldwide experience with PVE,
postoperative risk in patients who undergo PVE has yet
to be clearly quantiﬁed. In a preliminary study, a small
FLR (20 per cent or less of the estimated total liver volume
(TLV)) was associated with worse outcome20.
The aims of this study were to deﬁne the technical
and oncological safety of PVE, and to examine the
relationship between FLR volume after PVE, degree of
liver hypertrophy and outcomes of hepatic resection.
Methods
The records of 112 consecutive patients with hepatobiliary
malignancy who underwent PVE in preparation for major
or extended hepatectomy between September 1995 and
January 2006 were reviewed.
PVE was performed based on volumetry of the
anticipated FLR after evaluation by the operating surgeon
(E.K.A. or J.-N.V.). PVE was indicated when the FLR
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Fig. 1 a Change in tumour size after portal vein embolization (PVE) and b changes in future liver remnant (FLR) volume after right
PVE (21 patients) and right PVE extended to segment IV portal branches (right PVE + segment IV) (85 patients) in patients without
severe ﬁbrosis or cirrhosis. Values are median with interquartile ranges. *P = 0·007, †P < 0·001, (Wilcoxon test)
volume was 20 per cent or less of the estimated TLV in
patients with normal liver, 30 per cent or less in patients
with ﬁbrosis or severe liver injury7,21 and 40 per cent or
less in patients with cirrhosis22,23.
The FLR volume was measured directly using computed
tomography (CT) combined with three-dimensional
CT volumetry as described previously11,15. TLV was
calculated from the patient’s body surface area (BSA)
using a mathematical formula (TLV [cm3] = −794·41 +
1267·28 × BSA [m2])24,25. The ratio between FLR volume
and TLV was deﬁned as the standardized FLR (sFLR).
The difference between the sFLR before and after PVE
was deﬁned as the degree of hypertrophy (DH). Patients
with cirrhosis were excluded from the analysis of sFLR and
DH after PVE in relation to postoperative outcome after
hepatic resection.
PVE was performed as described previously26,27.
Embolization of segment IV was performed when an
extended right hepatectomy was planned on the basis of
tumour location.
All patients underwent abdominal CT with three-
dimensional CT volumetry 2–8 weeks after PVE to assess
the extent of compensatory hypertrophy.Tumour response
to PVE was reviewed retrospectively by a single radiologist
and evaluated according to Response Evaluation Criteria
in Solid Tumors28 in patients for whom both pre- and
post-PVE scans were available.
All patients underwent extended right or right hep-
atectomy with or without caudate lobectomy. The sur-
gical technique, intraoperative management and post-
operative care were as described previously1,29. All
patients with hilar cholangiocarcinoma underwent per-
cutaneous or endoscopic biliary drainage of the FLR
before PVE to achieve a bilirubin level of less than
34·2 µmol/l.
Perioperative morbidity was reported according to
the classiﬁcation proposed by Dindo et al.30. Grade
I and II complications were deﬁned as minor, and
grade III and IV complications as major. Postoperative
mortality was deﬁned as any death within 90 days after
surgery or within the hospital stay during which the
surgery was performed. Hepatic dysfunction was deﬁned
as a peak postoperative bilirubin level greater than
51·3 µmol/l1 or a prothrombin time longer than 18 s5.
Hepatic insufﬁciency was deﬁned as a peak postoperative
bilirubin level greater than 171 µmol/l unrelated to biliary
obstruction and/or clinically signiﬁcant ascites or hepatic
encephalopathy1.
Statistical analysis
Continuous data were expressed as median (95 per cent
conﬁdence interval), unless indicated otherwise, and
compared using the Mann–Whitney U test or Wilcoxon
test. Dichotomous variables were compared by means
of the χ2 test or Fisher’s exact test, as appropriate.
The relationship between liver regeneration and clinical
outcome was investigated using the sFLR after PVE and
the DH. Receiver–operator characteristic (ROC) curve
analysis was used to identify cut-off values of sFLR and
DH that predicted hepatic dysfunction.Cut-off values were
determined by seeking the largest sum of the sensitivity and
speciﬁcity values while maintaining the lowest likelihood
ratio of a negative test and the highest likelihood ratio
of a positive test. P < 0·050 was considered statistically
signiﬁcant.
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Fig. 2 Kinetics of future liver remnant (FLR) growth, plotted as median (with interquartile ranges) degree of hypertrophy (DH) after
portal vein embolization (PVE). The shaded zone (days 22–56 after PVE) identiﬁes the ‘plateau’ period during which the DH did not
change signiﬁcantly between measurement points. The number of measurements indicates the number of three-dimensional computed
tomography (CT) volumetric scans evaluated at each interval after PVE. The number of patients whose last CT evaluation occurred
during each interval is also shown. *P = 0·004 versus days 0–14; †P = 0·008 versus days 22–28 (Mann–Whitney U test)
Results
Clinicopathological features of the 112 patients studied
are shown in Table 1. The indications for PVE were
hepatic metastases in 65 patients (58·0 per cent) and
primary hepatobiliary malignancy in 47 (42·0 per cent).
Only four patients (3·6 per cent) presented with severe
ﬁbrosis or cirrhosis (Ishak score32 5–6). The remaining
108 patients had unremarkable pathological ﬁndings
(77 patients), hepatic injury (ﬁve) or ﬁbrosis (26). Twenty-
eight patients with colorectal liver metastases received
chemotherapy before PVE (median 4 (range 2–12) cycles),
which was discontinued a median of 6·5 weeks before
PVE. Five of these patients received more chemotherapy
treatment less than 2 weeks after PVE.
Technical and oncological safety of portal vein
embolization
Primary technical success of PVE was accomplished in 111
(99·1 per cent) of the 112 patients. One patient required a
second intervention to occlude an incompletely embolized
portal branch of the right anterior sector. PVE procedures
are summarized in Table 1. One patient underwent PVE
limited to segment IV because of pre-existing right portal
vein thrombosis.
Table 1 Patient characteristics
Sex ratio (M : F) 83 : 29
Mean (range) age (years) 60 (36–78)
Diabetes mellitus
Yes 35 (31·2)
No 77 (68·8)
Body mass index (kg/m2)
Mean (range) 27·7 (19·4–48·4)
< 25 kg/m2 34 (30·4)
≥ 25 kg/m2 73 (65·2)
Not available 5 (4·5)
Diagnosis
Colorectal metastases 50 (44·6)
Hepatocellular carcinoma 24 (21·4)
Hilar cholangiocarcinoma 14 (12·5)
Gallbladder cancer 6 (5·4)
Other malignant tumours 18 (16·1)
Non-tumorous liver
No pathological changes 77 (68·7)
Steatosis > 30% or steatohepatitis* 5 (4·5)
Fibrosis (F1–4†) 26 (23·2)
Severe fibrosis/cirrhosis (F5–6†) 4 (3·6)
Portal vein embolization
Right PVE + segment IV 86 (76·8)
Right PVE 24 (21·4)
Left PVE 1 (0·9)
Segment IV only 1 (0·9)
Values in parentheses are percentages unless indicated otherwise.
*Kleiner score 4 or more31. †Fibrosis score according to Ishak et al.32.
Right PVE + segment IV, right portal vein embolization (PVE) extended
to segment IV portal branches.
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Eight patients experienced complications after right
PVE extended to segment IV portal branches (right
PVE + segment IV). Four patients had partial portal
vein thromboses, which were treated with preoperative
anticoagulant therapy (one), surgical removal of the clot
(two), or left untreated because of systemic progression
of disease (one). One patient had a complete portal
vein thrombosis, which was treated with a 30-h local
infusion of recombinant tissue plasminogen activator
and mechanical thrombolysis. One patient developed a
subcapsular haematoma, and one had an oesophageal
haemorrhage. In one patient, a single coil migrated into
the segment III portal branch but this did not preclude
regeneration of the involved segment or subsequent liver
resection. One patient experienced a complication after
right PVE; migration of a coil and embolizing material to
the portal bifurcation was noted at the time of surgery,
and removed uneventfully. There was no difference in
the incidence of complications after right PVE + segment
IV and right PVE alone (P = 0·417). The patient who
underwent PVE limited to segment IV developed a left
portal vein thrombosis, and surgical resection was not
possible because of this and tumour progression. The
patient who underwent left PVE did not experience
complications.
Pre- and post-PVE scans were available for comparison
in 103 patients. Tumours were not measurable in 23
patients, 13 patients with hilar cholangiocarcinoma, six
with gallbladder cancer and fourwith colorectalmetastases.
In the remaining 80 patients the median tumour size was
5·3 (2·2 to 12·8) cm at baseline and 5·4 (1·9 to 15·2) after
PVE (Fig. 1a).
Regeneration after portal vein embolization
In 85 patients without cirrhosis who underwent right
PVE + segment IV, the absolute FLR volume increased
from 290 (180 to 505) cm3 before to 440 (294 to 716)
cm3 after PVE (P = 0·007) (Fig. 1b). The sFLR increased
from 16·6 (10·9 to 28·0) to 25·8 (16·8 to 40·0) per cent
(P = 0·007), giving a median DH of 8·8 (2·8 to 17·7) per
cent. In the 21 patients without cirrhosis who underwent
right PVE, the absolute FLR volume increased from 518
(274 to 945) cm3 before to 798 (269 to1352) cm3 after PVE
(P < 0·001) (Fig. 1b), and the sFLR increased from 28·1
(20·4 to 53·7) to 43·7 (21·1 to 67·8) per cent (P < 0·001);
the median DH was 10·9(1·4 to 24·6) per cent.
Among patients without cirrhosis, the absolute FLR
volumes and sFLRs measured before and after PVE, and
DH for segments I, II and III, were similar in patients
who underwent right PVE + segment IV and those who
had right PVE alone. The higher DH in patients who
had right PVE was due to signiﬁcant growth of segment
IV. The absolute segment IV volume increased from 227
(120 to 476) to 284 (145 to 544) cm3 (P < 0·001), and the
standardized segment IV volume (calculated as [segment
IV volume/estimated TLV] × 100) increased from 13·1
(6·6 to 25·1) to 17·1 (10·6 to 26·8) per cent (P < 0·001).
Segment IV DH was 3·4 (0·0 to 10·2) per cent.
Among patients without cirrhosis, the response to PVE
was similar in 28 patients who received preoperative
chemotherapy and 80 who did not. The two groups did
not differ with respect to absolute FLR volumes and
sFLR before and after PVE (P = 0·654, P = 0·723 and
P = 0·658, P = 0·617, respectively). Likewise, the DH
values were similar (9·0 (2·6 to 18·3) per cent in those
who had chemotherapy and 8·5 (2·7 to 24·6) per cent in
those who did not; P = 0·212).
In 31 patients with ﬁbrosis or liver injury, both the abso-
lute FLR volume and the sFLR signiﬁcantly increased after
PVE, from 435 (203 to 945) to 707(330 to 1197) cm3 (P <
0·001) and from25·2 (12·5 to 53·8) to 34·9 (21·5 to 66·6) per
cent (P < 0·001) respectively. TheDHwas 9·6 (1·7 to 22·5)
per cent. There was no difference in DH between patients
with and without underlying liver disease (P = 0·126).
Of the 112 patients, 94 were re-evaluated with one and
18 with multiple CT scans between 9 and 381 days after
Table 2 Surgical procedures and postoperative complications in
78 patients who had hepatic resection
No. of
patients
Procedures
Right PVE + segment IV 61 (78)
Extended right hepatectomy 34
Extended right hepatectomy + extrahepatic procedure* 27
Right PVE 17 (22)
Right hepatectomy 13
Right hepatectomy + extrahepatic procedure† 4
Two-stage resection 10 (13)
Postoperative complications 34 (44)
Minor (grade I–II) 18 (23)
Major (grade III–IV) 16 (21)
Hepatic dysfunction 12 (15)
Hepatic insufficiency 6 (8)
Death within 90 days (grade V) 2 (3)
Values in parentheses are percentages. Complications were graded
according to the classiﬁcation of Dindo et al.30. Extrahepatic procedures:
*resection of bile duct (n = 10), bile duct and portal vein (n = 2), portal
vein or inferior vena cava (n = 4), pancreas (n = 2), diaphragm (n = 5),
bowel (n = 2), lung (n = 1) and adrenal gland (n = 1); †resection of
diaphragm (n = 2), pancreas (n = 1) and lung (n = 1). Right
PVE + segment IV, right portal vein embolization (PVE) extended to
segment IV portal branches.
Copyright  2007 British Journal of Surgery Society Ltd www.bjs.co.uk British Journal of Surgery 2007; 94: 1386–1394
Published by John Wiley & Sons Ltd
1390 D. Ribero, E. K. Abdalla, D. C. Madoff, M. Donadon, E. M. Loyer and J.-N. Vauthey
PVE. Serial CT was carried out in some patients because
of insufﬁcient FLR growth or other factors leading to a
delay in the planned surgery.
Volumetric data obtained from all scans were used to
analyse the kinetics of FLR growth after PVE in patients
without cirrhosis (Fig. 2). The FLR volume signiﬁcantly
increased in the ﬁrst 3 weeks after the procedure (DH 3·2
(1·5 to 5·7) per cent for days 1–14 versus 7·4 (0·3 to 11·3) per
cent for days 15–21; P = 0·004). After this initial increase,
the DH reached a plateau phase of minimal regeneration
(DH 7·4 (0·3 to 11·3) per cent for days 15–21 versus 8·0
(0·4 to 14·9) per cent for days 22–28, P = 0·530; DH 8·0
(0·4 to 14·9) per cent for days 22–28 versus 8·9 (2·8 to 20·3)
per cent for days 29–56, P = 0·154) (Fig. 2). A slower rate
of liver regeneration continued in the following months: in
the 14 patients followed for more than 2 months (median
98 (57 to 339) days) the DH was 10·9 (4·2 to 24·7) per
cent. However, given the wide time distribution between
these measurements and the signiﬁcant difference in DH
values recorded (P = 0·008 for days 22–28 versus days
57–381), only measurements recorded during the plateau
period – between days 22 and 56 – were considered to be
homogeneous and therefore comparable regardless of the
time of acquisition.
Resectability and outcome
Seventeen patients (15·2 per cent) did not undergo surgery
after PVE because of extrahepatic (nine patients) or
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Fig. 3 Scatter plot of the incidence of hepatic dysfunction
according to degree of hypertrophy, stratiﬁed by standardized
future liver remnant (sFLR)
Table 3 Diagnostic capability of standardized future liver
remnant, hypertrophy rate and combined criteria in predicting
hepatic dysfunction
sFLR
≤ 20%
DH
≤ 5%
sFLR ≤ 20%
or DH ≤ 5%
Sensitivity (%) 60 67 80
Specificity (%) 98 96 94
Positive predictive value (%) 90 83 80
Negative predictive value (%) 89 91 94
LR+ 30·6 17·0 13·6
(4·2, 222·5) (4·2, 69·3) (4·4, 42·0)
LR− 0·41 0·35 0·21
(0·22, 0·76) (0·17, 0·71) (0·08, 0·59)
Values in parentheses are 95 per cent conﬁdence intervals. Only 66
patients with degree of hypertrophy (DH) calculated in the ‘plateau’
period were considered. sFLR, standardized future liver remnant; LR+,
likelihood ratio of positive test; LR−, likelihood ratio of negative test.
intrahepatic (one) progression of disease, inadequate
hepatic regeneration (ﬁve) or signiﬁcant medical co-
morbidities (two). Of the 95 patients who underwent
surgical exploration, 17 patients were excluded from
hepatic resection because of unexpected extrahepatic (ten
patients) or intrahepatic (two) disease precluding resection,
severe cirrhosis (two), severe intraoperative hypothermia
leading to coagulopathy (one), diffuse haemorrhage
(in a patient who had previously received prolonged
chemotherapy by hepatic arterial infusion) and hepatitis
(one). A total of 78 patients underwent hepatectomy
(resection rate 69·6 per cent). The surgical procedures
performed are summarized in Table 2. Of note, 27
(44 per cent) of 61 patients who underwent extended right
hepatectomy and four of 17 who had right hepatectomy
also had a synchronous extrahepatic procedure.
Thirty-four patients (44 per cent) experienced postoper-
ative complications. Grade II complications in 18 patients
(23 per cent) included self-limiting biliary ﬁstula (four),
hepatic dysfunction (seven), pneumonia (two), atrial ﬁb-
rillation (one), ﬂuid overload (one), urinary tract infec-
tion (one) and wound infection (two). Eleven patients
(14 per cent) experienced grade IIIa complications, includ-
ing bile leak/biloma (six), intra-abdominal ﬂuid collec-
tion (three), pleural effusion (one) and pancreatic ﬁstula
(one). Two patients (3 per cent) underwent reoperation for
small bowel perforation (grade IIIb complication). Three
patients (4 per cent) had grade IVa (life-threatening) com-
plications: liver insufﬁciency (one), pulmonary embolism
(one) and respiratory insufﬁciency (one).
Eighteen patients developed hepatic dysfunction, six of
whom experienced hepatic insufﬁciency and one died from
liver failure. Another patient died after surgery as a result
of a methicillin-resistant Staphylococcus aureus perihepatic
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Table 4 Short-term clinical outcome by standardized future liver remnant, degree of hypertrophy and combined criteria
sFLR DH sFLR or DH
≤ 20%
(n = 10)
> 20%
(n = 56) P†
≤ 5%
(n = 12)
> 5%
(n = 54) P†
≤ 20% or
≤ 5%
(n = 15)
> 20%
and > 5%
(n = 51) P†
Any complication 9 (90) 22 (39) 0·003 10 (83) 21 (39) 0·006 12 (80) 19 (37) 0·003
Major complication 5 (50) 9 (16) 0·028 5 (42) 9 (17) NS 7 (47) 7 (14) 0·011
Liver-related complication 9 (90) 13 (23) < 0·001 10 (83) 12 (22) < 0·001 12 (80) 10 (20) < 0·001
Hepatic dysfunction 9 (90) 6 (11) < 0·001 10 (83) 5 (9) < 0·001 12 (80) 3 (6) < 0·001
Hepatic insufficiency 3 (30) 1 (2) 0·009 2 (17) 2 (4) 0·148 3 (20) 1 (2) 0·034
Death within 90 days 1 (10) 1 (2) 0·282 1 (8) 1 (2) 0·332 2 (13) 0 (0) 0·049
Duration of hospital stay (days)* 8 (6–53) 8 (5–28) 0·312‡ 8.5 (6–53) 7 (5–28) 0·213‡ 8 (6–53) 7 (5–28) 0·119‡
Values in parentheses are percentages unless indicated otherwise; *values are median (range). Only 66 patients with degree of hypertrophy (DH)
calculated in the ‘plateau’ period were considered. sFLR, standardized future liver remnant. †χ2 test or Fisher’s exact test unless indicated otherwise;
‡Mann–Whitney U test.
collection complicated by haemoperitoneum. The 90-day
mortality rate was 3 per cent.
The median hospital stay after hepatic resection was 8
(range 5–53) days and there was no signiﬁcant difference
between patients with a normal liver and those with ﬁbrosis
or liver injury (7·0 versus 8·0 days; P = 0·891).
ROC curve analysis was performed to determine the
value of sFLR after PVE in predicting hepatic dysfunction.
The area under the curve was 0·81 (0·68 to 0·95) and the
cut-off value was 20 per cent. Fig. 3 shows the relationship
between postoperative hepatic function andDH in patients
stratiﬁed using the 20 per cent cut-off value for sFLR
after PVE. Hepatic dysfunction was more common in
patients with a small sFLR, and appeared to be related to
a small DH.
ROC curve analysis of DH in predicting hepatic
dysfunction yielded an area under the curve of 0·84 (0·70 to
1·00) with a cut-off value of 5 per cent. To avoid bias from
inclusion of patients with liver in a signiﬁcant regeneration
phase, only the 66 patients with the DH calculated in the
plateau period were considered.
These analyses indicated that patients with a sFLR
of more than 20 per cent or a DH of more than
5 per cent had good outcomes. In contrast, patients with
a sFLR of 20 per cent or less, regardless of DH, and
patients with a DH of 5 per cent or less, regardless of
sFLR, had poor outcomes. Table 3 shows the diagnostic
characteristics of sFLR and DH cut-off values in the
plateau period population. Considered separately, both
sFLR andDHdisplayed high speciﬁcity but low sensitivity.
The combination of sFLR and DH had a speciﬁcity of
94 per cent and a sensitivity of 80 per cent (Table 3). The
combination of sFLR and DHwas also useful in predicting
clinical outcomes (Table 4).
Impaired liver regeneration after PVEwas not associated
with any of the patient factors tested (sex, age, diabetes
and body mass index) or liver-related factors (presence
of ﬁbrosis, or steatosis/steatohepatitis); there was no
signiﬁcant difference between DH 5 per cent or less
versus more than 5 per cent for any factor (P = 0·503,
P = 0·187, P = 0·408, P = 0·169, P = 0·270 and P =
0·567 respectively).
Discussion
Embolization of the entire tumour-bearing liver before
hepatic resection is safe both technically and oncologically.
It appears that DH contributes additional prognostic
information beyond that provided by volumetric evaluation
in patients undergoing PVE before hepatic resection.
Analysis of hepatic regeneration after PVE in patients
without cirrhosis revealed an early phase of regeneration
during the ﬁrst 3 weeks followed by a plateau during which
the FLR volume increased only slightly. The present study
expands on the results of a previous analysis33. Although
some authors re-evaluate patients after 2 weeks33–36, the
present results show that a steady state of regeneration
has not been reached by this time and that 21 days is
the minimum interval needed before the hypertrophic
response to PVE is assessed. Patients who exhibit slow
liver growth and those with small sFLRs after 3 weeks are
unlikely to experience rapid regeneration beyond this time
point, and this should be taken into account when planning
treatment.
Identiﬁcation of the plateau period permitted deﬁnition
of a homogeneous group of patients in a steady-state
phase of liver growth. This provided the basis for analysis
of the signiﬁcance of the ‘static’ (sFLR) and ‘dynamic’
(DH) information obtained by CT volumetry. The FLR
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volume and the sFLR provide no information about change
in volume over time, whereas the DH, a measure of
liver growth, is a dynamic, time-dependent variable. The
ﬁndings of the present study indicate that approximately
75 per cent of the growth in the FLR in the ﬁrst 2 months
after PVE occurs in the ﬁrst 3 weeks, so early evaluations
may underestimate the real response to the hypertrophic
stimulus and result in overestimation of the postoperative
risk.
Both sFLR after PVE (20 per cent or less) and DH
(5 per cent or less) accurately predicted the likelihood of
postoperative hepatic dysfunction. Individually, sFLR and
DH had high speciﬁcity and relatively low sensitivity, but
when combined predicted hepatic dysfunction with high
sensitivity and correlated with clinical outcome. Patients
with a sFLR of 20 per cent or less or DH of not more than
5 per cent had a signiﬁcantly higher risk of overall, major
and liver-related complications, and hepatic dysfunction
and insufﬁciency. They also had a higher 90-day mortality
rate (Table 4).
The optimal extent of PVE before planned extended
right hepatectomy has been debated27. Embolization of
segment IV portal branches in patients with segment IV
involvement has been criticized because of the risk of
inadvertent occlusion of the portal veins supplying the
anticipated FLR37. Segment IV embolization is advised for
both technical27 (hypertrophy of this segment increases
the parenchymal transection area) and oncological38,39
(segment IV hypertrophy may be associated with tumour
growth in the non-embolized segments) reasons. The
present study has conﬁrmed the safety and effectiveness
of right PVE + segment IV. Only one patient (1 per cent)
experienced reﬂux of embolizing material into the portal
veins of the FLR, compared with 6·3 per cent after 188
right PVEs reported by Di Stefano and colleagues40.
Consistent with previous ﬁndings40,41, adverse events
occurred in ten (8·9 per cent) of 112 patients in the
present study, but there was no difference in the
incidence of complications after right PVE and right
PVE + segment IV.
In patients with colorectal liver metastases, PVE is
frequently part of a multimodal treatment that includes
preoperative chemotherapy. Liver injuries associated with
systemic chemotherapy have been recognized42–44, which
raises the concern that chemotherapy might impair the
regenerative response to PVE. However, in keeping with
previous ﬁndings45,46, preoperative chemotherapy did not
impair hepatic regeneration after PVE in the present series.
This study has demonstrated the importance of the
hypertrophic response of the liver to PVE, and the role
of low sFLR and DH values as predictors of poor clinical
outcome. The cut-off values in this series were determined
in patients with moderate hepatic injury at worst and
further studies are required to deﬁne the most appropriate
values for patients who have cirrhosis6 or hepatic injury
from extensive chemotherapy42.
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